Services

Toxicology

Pharmacology

Animal Model Development

Medical Device Testing

In Vitro Screening

Custom Assay Development

Vivarium Rental

Histology

Therapeutic Areas

Oncology

Immunology & Inflammation

Neurology / CNS

Cardiovascular

Dermatology & Wound Healing

Metabolism

Gastroenterology

Hepatology

Pulmonology

Infectious Diseases & Sepsis

Musculoskeletal

Nephrology & Urology

Species

Non-human Primates

Dogs

Minipigs / Pigs

Rabbits

Mice

Rats

Sheep

Guinea Pigs

Hamsters

Other Species

Capabilities

GLP / IND-Enabling Studies

Small and Large Animal Housing

Bioanalytical Platforms

About

News

Contact

Careers

Request a Quote

Logo
☰
  • Services ⌄
    • Toxicology
    • Pharmacology
    • Animal Model Development
    • Medical Device Testing
    • In Vitro Screening
    • Custom Assay Development
    • Vivarium Rental
    • Histology
  • Therapeutic Areas ⌄
    • Oncology
    • Immunology & Inflammation
    • Neurology / CNS
    • Cardiovascular
    • Dermatology & Wound Healing
    • Metabolism
    • Gastroenterology
    • Hepatology
    • Pulmonology
    • Infectious Diseases & Sepsis
    • Musculoskeletal
    • Nephrology & Urology
  • Species ⌄
    • Non-human Primates
    • Dogs
    • Minipigs / Pigs
    • Rabbits
    • Mice
    • Rats
    • Sheep
    • Guinea Pigs
    • Hamsters
    • Other Species
  • Capabilities ⌄
    • GLP / IND-Enabling Studies
    • Small and Large Animal Housing
    • Bioanalytical Platforms
  • About ⌄
    • News
  • Contact ⌄
    • Careers
    • Request a Quote

Mylan’s Generic Version of Biogen’s MS Drug Gets FDA Approval

  • Post author:Sam
  • Post published:August 20, 2020
  • Post category:Devices & Diagnostics Letter

Mylan has launched the product in 120mg and 240mg delayed-release capsule forms. Source: Devices & Diagnostics Letter

Continue ReadingMylan’s Generic Version of Biogen’s MS Drug Gets FDA Approval

OpGen Earns CE Mark for COVID-19 Diagnostic

  • Post author:Sam
  • Post published:August 20, 2020
  • Post category:Devices & Diagnostics Letter

The diagnostic runs on real-time PCR detection systems, including Applied Biosystems’ QuantStudio 5 and Bio-Rad’s CFX96. Source: Devices & Diagnostics Letter

Continue ReadingOpGen Earns CE Mark for COVID-19 Diagnostic

Trump Criticizes FDA Delay of Convalescent Plasma EUA

  • Post author:Sam
  • Post published:August 20, 2020
  • Post category:Devices & Diagnostics Letter

President Trump is lashing out at the FDA’s decision to hold off issuing an Emergency Use Authorization (EUA) for using convalescent plasma to treat COVID-19 patients. Source: Devices & Diagnostics…

Continue ReadingTrump Criticizes FDA Delay of Convalescent Plasma EUA

Smiths Medical Pulls Infusion Pumps, Citing Software Error

  • Post author:Sam
  • Post published:August 20, 2020
  • Post category:Devices & Diagnostics Letter

The company expects to release software updates late next year that will fix the problem. Source: Devices & Diagnostics Letter

Continue ReadingSmiths Medical Pulls Infusion Pumps, Citing Software Error

EU, CureVac Near Advanced Purchase Agreement for COVID-19 Vaccine

  • Post author:Sam
  • Post published:August 20, 2020
  • Post category:Devices & Diagnostics Letter

German vaccine maker CureVac and the European Union (EU) are close to finalizing a supply deal for the company’s COVID-19 vaccine candidate that will stock the EU with hundreds of…

Continue ReadingEU, CureVac Near Advanced Purchase Agreement for COVID-19 Vaccine

LumiraDx Rapid COVID-19 Test Authorized for Emergency Use

  • Post author:Sam
  • Post published:August 20, 2020
  • Post category:Devices & Diagnostics Letter

The company said it plans to produce 2 million tests in September, increasing to 10 million tests in December. Source: Devices & Diagnostics Letter

Continue ReadingLumiraDx Rapid COVID-19 Test Authorized for Emergency Use

Sinopharm to Begin Phase 3 Trial of its COVID-19 Vaccine Candidate in Peru

  • Post author:Sam
  • Post published:August 20, 2020
  • Post category:Devices & Diagnostics Letter

Sinopharm has announced that it will launch another phase 3 trial of its experimental COVID-19 vaccine candidate, this time in Peru, following a greenlight from the Peruvian health regulator. Source:…

Continue ReadingSinopharm to Begin Phase 3 Trial of its COVID-19 Vaccine Candidate in Peru

J&J to Start Largest Phase 3 Vaccine Trial Yet in September

  • Post author:Sam
  • Post published:August 20, 2020
  • Post category:Devices & Diagnostics Letter

Johnson & Johnson (J&J) expects to begin the largest late-stage trial for a COVID-19 vaccine candidate to date early next month if results from its early-stage studies pan out. Source:…

Continue ReadingJ&J to Start Largest Phase 3 Vaccine Trial Yet in September

Siemens Healthineers’ MRI Software Cleared

  • Post author:Sam
  • Post published:August 20, 2020
  • Post category:Devices & Diagnostics Letter

The software can be used with scanners made by Siemens or other manufacturers. Source: Devices & Diagnostics Letter

Continue ReadingSiemens Healthineers’ MRI Software Cleared

Pfizer-BioNTech COVID-19 Vaccine Moves Into Pivotal Trial

  • Post author:Sam
  • Post published:August 20, 2020
  • Post category:Drug Industry Daily

Pfizer’s and BioNTech’s experimental COVID-19 vaccine BNT162b2 has been chosen for a phase 2/3 efficacy study of 9,000 participants following its success in a phase 1 trial. Source: Drug Industry…

Continue ReadingPfizer-BioNTech COVID-19 Vaccine Moves Into Pivotal Trial
  • 1
  • 2
  • 3
  • Go to the next page

Stay Connected

Keep up with the latest news & insights.

Contact Us

Phone:
+1 858-605-5882
Fax:
+1 858-605-5916
Email:
info@biolegacyresearch.com
Mail:
6042 Cornerstone Court W
Suite E
San Diego, CA 92121
Social::
© 2025 BioLegacy Research. All rights reserved.
BioLegacy research is a PharmaLegacy Laboratories company